Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS‐CoV‐2 as well as its variants...
Saved in:
| Published in | Bioengineering & translational medicine Vol. 8; no. 5; pp. e10410 - n/a |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.09.2023
Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS‐CoV‐2 as well as its variants. Antibody against SARS‐CoV‐2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID‐19. We, therefore, developed a quick and precise phase‐sensitive surface plasmon resonance (PS‐SPR) biosensor integrated with a novel generated anti‐S monoclonal antibody (S‐mAb). Our results indicated that the newly generated S‐mAb could detect the original SARS‐CoV‐2 strain along with its variants. In addition, a SARS‐CoV‐2 pseudovirus, which could be processed in BSL‐2 facility was generated for evaluation of sensitivity and specificity of the assays including PS‐SPR, homemade target‐captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Experimentally, PS‐SPR exerted high sensitivity to detect SARS‐CoV‐2 pseudovirus at 589 copies/ml, with 7‐fold and 70‐fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target‐captured ELISA (4 × 10
3
copies/ml) and SRAT (4 × 10
4
copies/ml), using the identical antibody. Moreover, the PS‐SPR was applied in the measurement of mimic clinical samples containing the SARS‐CoV‐2 pseudovirus mixed with nasal mucosa. The detection limit of PS‐SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target‐captured ELISA (4 × 10
4
copies/ml) and SRAT (4 × 10
5
copies/ml) and is comparable with qRT‐PCR (1250 copies/ml). Finally, the ability of PS‐SPR to detect SARS‐CoV‐2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S‐mAb integrated into PS‐SPR biosensor demonstrates high sensitivity and is time‐saving in SARS‐CoV‐2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re‐emerging pathogenic detection platforms. |
|---|---|
| AbstractList | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in late 2019 leading to the COVID-19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS-CoV-2 as well as its variants. Antibody against SARS-CoV-2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID-19. We, therefore, developed a quick and precise phase-sensitive surface plasmon resonance (PS-SPR) biosensor integrated with a novel generated anti-S monoclonal antibody (S-mAb). Our results indicated that the newly generated S-mAb could detect the original SARS-CoV-2 strain along with its variants. In addition, a SARS-CoV-2 pseudovirus, which could be processed in BSL-2 facility was generated for evaluation of sensitivity and specificity of the assays including PS-SPR, homemade target-captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Experimentally, PS-SPR exerted high sensitivity to detect SARS-CoV-2 pseudovirus at 589 copies/ml, with 7-fold and 70-fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target-captured ELISA (4 × 103 copies/ml) and SRAT (4 × 104 copies/ml), using the identical antibody. Moreover, the PS-SPR was applied in the measurement of mimic clinical samples containing the SARS-CoV-2 pseudovirus mixed with nasal mucosa. The detection limit of PS-SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target-captured ELISA (4 × 104 copies/ml) and SRAT (4 × 105 copies/ml) and is comparable with qRT-PCR (1250 copies/ml). Finally, the ability of PS-SPR to detect SARS-CoV-2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S-mAb integrated into PS-SPR biosensor demonstrates high sensitivity and is time-saving in SARS-CoV-2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re-emerging pathogenic detection platforms. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in late 2019 leading to the COVID-19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS-CoV-2 as well as its variants. Antibody against SARS-CoV-2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID-19. We, therefore, developed a quick and precise phase-sensitive surface plasmon resonance (PS-SPR) biosensor integrated with a novel generated anti-S monoclonal antibody (S-mAb). Our results indicated that the newly generated S-mAb could detect the original SARS-CoV-2 strain along with its variants. In addition, a SARS-CoV-2 pseudovirus, which could be processed in BSL-2 facility was generated for evaluation of sensitivity and specificity of the assays including PS-SPR, homemade target-captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Experimentally, PS-SPR exerted high sensitivity to detect SARS-CoV-2 pseudovirus at 589 copies/ml, with 7-fold and 70-fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target-captured ELISA (4 × 103 copies/ml) and SRAT (4 × 104 copies/ml), using the identical antibody. Moreover, the PS-SPR was applied in the measurement of mimic clinical samples containing the SARS-CoV-2 pseudovirus mixed with nasal mucosa. The detection limit of PS-SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target-captured ELISA (4 × 104 copies/ml) and SRAT (4 × 105 copies/ml) and is comparable with qRT-PCR (1250 copies/ml). Finally, the ability of PS-SPR to detect SARS-CoV-2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S-mAb integrated into PS-SPR biosensor demonstrates high sensitivity and is time-saving in SARS-CoV-2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re-emerging pathogenic detection platforms.The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in late 2019 leading to the COVID-19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS-CoV-2 as well as its variants. Antibody against SARS-CoV-2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID-19. We, therefore, developed a quick and precise phase-sensitive surface plasmon resonance (PS-SPR) biosensor integrated with a novel generated anti-S monoclonal antibody (S-mAb). Our results indicated that the newly generated S-mAb could detect the original SARS-CoV-2 strain along with its variants. In addition, a SARS-CoV-2 pseudovirus, which could be processed in BSL-2 facility was generated for evaluation of sensitivity and specificity of the assays including PS-SPR, homemade target-captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Experimentally, PS-SPR exerted high sensitivity to detect SARS-CoV-2 pseudovirus at 589 copies/ml, with 7-fold and 70-fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target-captured ELISA (4 × 103 copies/ml) and SRAT (4 × 104 copies/ml), using the identical antibody. Moreover, the PS-SPR was applied in the measurement of mimic clinical samples containing the SARS-CoV-2 pseudovirus mixed with nasal mucosa. The detection limit of PS-SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target-captured ELISA (4 × 104 copies/ml) and SRAT (4 × 105 copies/ml) and is comparable with qRT-PCR (1250 copies/ml). Finally, the ability of PS-SPR to detect SARS-CoV-2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S-mAb integrated into PS-SPR biosensor demonstrates high sensitivity and is time-saving in SARS-CoV-2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re-emerging pathogenic detection platforms. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in late 2019 leading to the COVID-19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS-CoV-2 as well as its variants. Antibody against SARS-CoV-2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID-19. We, therefore, developed a quick and precise phase-sensitive surface plasmon resonance (PS-SPR) biosensor integrated with a novel generated anti-S monoclonal antibody (S-mAb). Our results indicated that the newly generated S-mAb could detect the original SARS-CoV-2 strain along with its variants. In addition, a SARS-CoV-2 pseudovirus, which could be processed in BSL-2 facility was generated for evaluation of sensitivity and specificity of the assays including PS-SPR, homemade target-captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Experimentally, PS-SPR exerted high sensitivity to detect SARS-CoV-2 pseudovirus at 589 copies/ml, with 7-fold and 70-fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target-captured ELISA (4 × 10 copies/ml) and SRAT (4 × 10 copies/ml), using the identical antibody. Moreover, the PS-SPR was applied in the measurement of mimic clinical samples containing the SARS-CoV-2 pseudovirus mixed with nasal mucosa. The detection limit of PS-SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target-captured ELISA (4 × 10 copies/ml) and SRAT (4 × 10 copies/ml) and is comparable with qRT-PCR (1250 copies/ml). Finally, the ability of PS-SPR to detect SARS-CoV-2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S-mAb integrated into PS-SPR biosensor demonstrates high sensitivity and is time-saving in SARS-CoV-2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re-emerging pathogenic detection platforms. The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS‐CoV‐2 as well as its variants. Antibody against SARS‐CoV‐2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID‐19. We, therefore, developed a quick and precise phase‐sensitive surface plasmon resonance (PS‐SPR) biosensor integrated with a novel generated anti‐S monoclonal antibody (S‐mAb). Our results indicated that the newly generated S‐mAb could detect the original SARS‐CoV‐2 strain along with its variants. In addition, a SARS‐CoV‐2 pseudovirus, which could be processed in BSL‐2 facility was generated for evaluation of sensitivity and specificity of the assays including PS‐SPR, homemade target‐captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Experimentally, PS‐SPR exerted high sensitivity to detect SARS‐CoV‐2 pseudovirus at 589 copies/ml, with 7‐fold and 70‐fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target‐captured ELISA (4 × 10 3 copies/ml) and SRAT (4 × 10 4 copies/ml), using the identical antibody. Moreover, the PS‐SPR was applied in the measurement of mimic clinical samples containing the SARS‐CoV‐2 pseudovirus mixed with nasal mucosa. The detection limit of PS‐SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target‐captured ELISA (4 × 10 4 copies/ml) and SRAT (4 × 10 5 copies/ml) and is comparable with qRT‐PCR (1250 copies/ml). Finally, the ability of PS‐SPR to detect SARS‐CoV‐2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S‐mAb integrated into PS‐SPR biosensor demonstrates high sensitivity and is time‐saving in SARS‐CoV‐2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re‐emerging pathogenic detection platforms. Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered socioeconomic turmoil worldwide. A precise, prompt, and affordable diagnostic assay is essential for the detection of SARS‐CoV‐2 as well as its variants. Antibody against SARS‐CoV‐2 spike (S) protein was reported as a suitable strategy for therapy and diagnosis of COVID‐19. We, therefore, developed a quick and precise phase‐sensitive surface plasmon resonance (PS‐SPR) biosensor integrated with a novel generated anti‐S monoclonal antibody (S‐mAb). Our results indicated that the newly generated S‐mAb could detect the original SARS‐CoV‐2 strain along with its variants. In addition, a SARS‐CoV‐2 pseudovirus, which could be processed in BSL‐2 facility was generated for evaluation of sensitivity and specificity of the assays including PS‐SPR, homemade target‐captured ELISA, spike rapid antigen test (SRAT), and quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Experimentally, PS‐SPR exerted high sensitivity to detect SARS‐CoV‐2 pseudovirus at 589 copies/ml, with 7‐fold and 70‐fold increase in sensitivity when compared with the two conventional immunoassays, including homemade target‐captured ELISA (4 × 103 copies/ml) and SRAT (4 × 104 copies/ml), using the identical antibody. Moreover, the PS‐SPR was applied in the measurement of mimic clinical samples containing the SARS‐CoV‐2 pseudovirus mixed with nasal mucosa. The detection limit of PS‐SPR is calculated to be 1725 copies/ml, which has higher accuracy than homemade target‐captured ELISA (4 × 104 copies/ml) and SRAT (4 × 105 copies/ml) and is comparable with qRT‐PCR (1250 copies/ml). Finally, the ability of PS‐SPR to detect SARS‐CoV‐2 in real clinical specimens was further demonstrated, and the assay time was less than 10 min. Taken together, our results indicate that this novel S‐mAb integrated into PS‐SPR biosensor demonstrates high sensitivity and is time‐saving in SARS‐CoV‐2 virus detection. This study suggests that incorporation of a high specific recognizer in SPR biosensor is an alternative strategy that could be applied in developing other emerging or re‐emerging pathogenic detection platforms. |
| Author | Chen, Kai‐Ren Yang, Zih‐Syuan Hsiao, Hui‐Hua Wang, Sheng‐Fan Li, Meng‐Chi Kuo, Chien‐Cheng Lin, Yu‐Ting Chen, Yen‐Hsu Urbina, Aspiro Nayim Lin, Yu‐Xen Lin, Shang‐Yi Assavalapsakul, Wanchai Thitithanyanont, Arunee Su, Li‐Chen Lin, Chih‐Yen Wang, Wen‐Hung Lin, Kun‐Der Yu, Ming‐Lung |
| AuthorAffiliation | 5 Thin Film Technology Center National Central University Taoyuan Taiwan 17 Department of Medical Research Kaohsiung Medical University Hospital Kaohsiung Taiwan 9 Department of Optics and Photonics National Central University Taoyuan Taiwan 3 School of Medicine, College of Medicine National Sun Yat‐Sen University Kaohsiung Taiwan 13 Department of Laboratory Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan 4 Division of Infection Disease, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan 10 TeraOptics Corporation Taoyuan Taiwan 14 Hepatobiliary Section, Department of Internal Medicine, and Hepatitis Center Kaohsiung Medical University Hospital Kaohsiung Taiwan 11 Division of Hematology and Oncology, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan 16 Organic Electronics Research Center Ming Chi University of Technology New Taipei City Taiwan 2 Center for Tropical Medicine and Infectious Disease Research Kao |
| AuthorAffiliation_xml | – name: 1 Department of Medical Laboratory Science and Biotechnology Kaohsiung Medical University Kaohsiung Taiwan – name: 11 Division of Hematology and Oncology, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – name: 3 School of Medicine, College of Medicine National Sun Yat‐Sen University Kaohsiung Taiwan – name: 7 Department of Microbiology, Faculty of Science Chulalongkorn University Bangkok Thailand – name: 9 Department of Optics and Photonics National Central University Taoyuan Taiwan – name: 6 Optical Sciences Center National Central University Taoyuan Taiwan – name: 14 Hepatobiliary Section, Department of Internal Medicine, and Hepatitis Center Kaohsiung Medical University Hospital Kaohsiung Taiwan – name: 4 Division of Infection Disease, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – name: 5 Thin Film Technology Center National Central University Taoyuan Taiwan – name: 8 Department of Microbiology, Faculty of Science Mahidol University Bangkok Thailand – name: 17 Department of Medical Research Kaohsiung Medical University Hospital Kaohsiung Taiwan – name: 10 TeraOptics Corporation Taoyuan Taiwan – name: 2 Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan – name: 13 Department of Laboratory Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – name: 15 General Education Center Ming Chi University of Technology New Taipei City Taiwan – name: 12 Division of Endocrinology and Metabolism Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan – name: 16 Organic Electronics Research Center Ming Chi University of Technology New Taipei City Taiwan |
| Author_xml | – sequence: 1 givenname: Chih‐Yen surname: Lin fullname: Lin, Chih‐Yen organization: Department of Medical Laboratory Science and Biotechnology Kaohsiung Medical University Kaohsiung Taiwan, Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan – sequence: 2 givenname: Wen‐Hung surname: Wang fullname: Wang, Wen‐Hung organization: Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan, School of Medicine, College of Medicine National Sun Yat‐Sen University Kaohsiung Taiwan, Division of Infection Disease, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – sequence: 3 givenname: Meng‐Chi surname: Li fullname: Li, Meng‐Chi organization: Thin Film Technology Center National Central University Taoyuan Taiwan, Optical Sciences Center National Central University Taoyuan Taiwan – sequence: 4 givenname: Yu‐Ting surname: Lin fullname: Lin, Yu‐Ting organization: Department of Medical Laboratory Science and Biotechnology Kaohsiung Medical University Kaohsiung Taiwan, Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan – sequence: 5 givenname: Zih‐Syuan surname: Yang fullname: Yang, Zih‐Syuan organization: Department of Medical Laboratory Science and Biotechnology Kaohsiung Medical University Kaohsiung Taiwan, Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan – sequence: 6 givenname: Aspiro Nayim surname: Urbina fullname: Urbina, Aspiro Nayim organization: Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan – sequence: 7 givenname: Wanchai surname: Assavalapsakul fullname: Assavalapsakul, Wanchai organization: Department of Microbiology, Faculty of Science Chulalongkorn University Bangkok Thailand – sequence: 8 givenname: Arunee surname: Thitithanyanont fullname: Thitithanyanont, Arunee organization: Department of Microbiology, Faculty of Science Mahidol University Bangkok Thailand – sequence: 9 givenname: Kai‐Ren surname: Chen fullname: Chen, Kai‐Ren organization: Department of Optics and Photonics National Central University Taoyuan Taiwan – sequence: 10 givenname: Chien‐Cheng surname: Kuo fullname: Kuo, Chien‐Cheng organization: Thin Film Technology Center National Central University Taoyuan Taiwan, Department of Optics and Photonics National Central University Taoyuan Taiwan – sequence: 11 givenname: Yu‐Xen surname: Lin fullname: Lin, Yu‐Xen organization: TeraOptics Corporation Taoyuan Taiwan – sequence: 12 givenname: Hui‐Hua surname: Hsiao fullname: Hsiao, Hui‐Hua organization: Division of Hematology and Oncology, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – sequence: 13 givenname: Kun‐Der surname: Lin fullname: Lin, Kun‐Der organization: Division of Endocrinology and Metabolism Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan – sequence: 14 givenname: Shang‐Yi surname: Lin fullname: Lin, Shang‐Yi organization: Division of Infection Disease, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan, Department of Laboratory Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – sequence: 15 givenname: Yen‐Hsu surname: Chen fullname: Chen, Yen‐Hsu organization: Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan, School of Medicine, College of Medicine National Sun Yat‐Sen University Kaohsiung Taiwan, Division of Infection Disease, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan – sequence: 16 givenname: Ming‐Lung surname: Yu fullname: Yu, Ming‐Lung organization: School of Medicine, College of Medicine National Sun Yat‐Sen University Kaohsiung Taiwan, Hepatobiliary Section, Department of Internal Medicine, and Hepatitis Center Kaohsiung Medical University Hospital Kaohsiung Taiwan – sequence: 17 givenname: Li‐Chen orcidid: 0000-0003-0731-3758 surname: Su fullname: Su, Li‐Chen organization: General Education Center Ming Chi University of Technology New Taipei City Taiwan, Organic Electronics Research Center Ming Chi University of Technology New Taipei City Taiwan – sequence: 18 givenname: Sheng‐Fan surname: Wang fullname: Wang, Sheng‐Fan organization: Department of Medical Laboratory Science and Biotechnology Kaohsiung Medical University Kaohsiung Taiwan, Center for Tropical Medicine and Infectious Disease Research Kaohsiung Medical University Kaohsiung Taiwan, Department of Medical Research Kaohsiung Medical University Hospital Kaohsiung Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36248235$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1rFDEUhoNUbF174w-QgDcirOZ7JjdCLX4UCt7odchkzuxmmUnWJLNlf4t_1my3lbZ4lXDOe568Obwv0UmIARB6TckHSgj72JWJ1Zug5Bk6Y7wlS9UoevLgforOc94QQqiinLfiBTrliomWcXmG_nyOMRcfVrisAfdQwBUfA95CGmKabHCA44Az7CABtm4ugBPkrU-2xLTHeR_6FCfALqYY7M6nOWOGC-RSiSnOqzW2dTxkX_yusrbFOzvizsdDMSZ848saB7jBea6P-lqxofgu9vtX6Plgxwznd-cC_fr65efl9-X1j29XlxfXSye5LkvOGB06RSnQlhBHmXZWNJyR-kXZSSIVc8NQu9opAloMTmvVNqrTgredsHyBro7cPtqN2SY_2bQ30XpzW4hpZWyqtkcwXOhWCkJ7pnqhueqsbJxqek6llrz6WaBPR9Z27iboHYSS7PgI-rgT_Nqs4s7U8ZZoVQHv7gAp_p7rGs3ks4NxtAHinA1rmBSCMqWr9O0T6SbOKdRVGdYqRqVolaiqNw8d_bNyn4EqIEeBSzHnBINxvthDCqpBPxpKzCFp5pA0c5u0OvL-ycg99T_iv1u91fo |
| CitedBy_id | crossref_primary_10_1021_acs_analchem_2c05661 crossref_primary_10_1002_adom_202400849 crossref_primary_10_1002_btm2_10621 crossref_primary_10_2174_0115680266289898240322073258 crossref_primary_10_1016_j_aca_2025_343640 |
| Cites_doi | 10.1080/14737159.2020.1757437 10.1016/j.cell.2021.08.017 10.1021/acssensors.1c02215 10.3389/fmolb.2021.607886 10.1016/S0966-842X(96)10076-7 10.1007/s42485-021-00060-3 10.1038/s41467-021-26401-w 10.1128/JVI.00635-20 10.1016/j.cca.2020.03.009 10.1016/j.bios.2021.113649 10.3390/genes12010016 10.1128/jvi.70.6.3852-3862.1996 10.3389/fimmu.2021.732756 10.1016/j.bios.2016.01.040 10.1001/jama.2020.0757 10.1016/j.optcom.2015.06.011 10.1016/j.bsheal.2020.08.004 10.1038/s41467-021-22785-x 10.1186/s13578-021-00643-z 10.1016/j.bios.2016.06.064 10.1021/acs.analchem.6b03511 10.7717/peerj.10234 10.3390/chemosensors9120330 10.3390/v13010046 10.2217/fvl-2020-0204 10.1007/s00604-021-04974-z 10.1021/acs.analchem.1c01093 10.1016/j.diagmicrobio.2020.115094 10.1007/s40588-021-00157-9 10.1016/j.bios.2021.113595 10.7150/ijbs.59184 10.3390/diagnostics11071190 10.1038/s41467-020-18319-6 10.1016/j.bios.2017.01.043 10.1021/acs.analchem.0c05438 10.1016/j.jiph.2020.03.019 10.1038/s41586-020-2012-7 10.1016/j.gendis.2020.07.006 10.1128/JCM.43.4.1851-1857.2005 10.1038/s41563-020-00906-z 10.1016/j.lanwpc.2021.100276 10.1002/jmv.1890060309 10.1128/jvi.01837-21 10.14202/vetworld.2021.190-199 10.1038/s41579-020-00459-7 10.3390/ijms22063060 10.1016/j.bbrc.2009.03.119 10.1038/s41579-021-00573-0 10.1038/s41586-020-2180-5 10.1016/j.bios.2018.03.051 10.1038/s41580-021-00418-x 10.3390/bios11030075 10.1016/j.bios.2020.112715 10.1056/NEJMoa2001017 10.3390/biology10090880 10.1016/j.cell.2022.01.001 10.1016/j.bios.2021.113497 10.7554/eLife.70658 10.1038/s41587-020-0631-z 10.3390/s21227615 10.1016/j.molmed.2004.03.003 10.1016/j.jviromet.2014.10.019 10.1073/pnas.2003138117 10.3389/fmed.2021.797109 10.1016/j.dci.2016.10.010 10.1038/s41467-021-27369-3 10.1002/rmv.2282 10.1021/acs.analchem.7b03934 10.1038/nmeth.2570 10.1073/pnas.1815329116 10.1021/acsnano.0c10035 10.1016/j.pathol.2020.09.006 10.1021/acssynbio.1c00499 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. |
| Copyright_xml | – notice: 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. – notice: 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. |
| DBID | AAYXX CITATION NPM 8FE 8FG ABJCF ABUWG AFKRA AZQEC BENPR BGLVJ CCPQU DWQXO HCIFZ L6V M7S PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PTHSS 7X8 5PM DOA |
| DOI | 10.1002/btm2.10410 |
| DatabaseName | CrossRef PubMed ProQuest SciTech Collection ProQuest Technology Collection Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Technology Collection ProQuest One Community College ProQuest Central ProQuest SciTech Premium Collection ProQuest Engineering Collection Engineering Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (subscription) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Engineering collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Engineering Database Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Technology Collection ProQuest SciTech Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Engineering Collection ProQuest One Academic UKI Edition ProQuest Central Korea Materials Science & Engineering Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) Engineering Collection MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| DocumentTitleAlternate | Lin et al |
| EISSN | 2380-6761 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_34985401d26d4936ba57c67d315953c5 PMC9538096 36248235 10_1002_btm2_10410 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Kaohsiung Medical University Research Center Grant grantid: KMU‐TC111B01 – fundername: Ministry of Science and Technology, Taiwan grantid: MOST 107‐2923‐B‐005‐005‐MY3; MOST 108‐2112‐M‐131‐002‐MY3; MOST 108‐2320‐B‐037‐035‐MY3; MOST 108‐2918‐I‐037‐001; MOST 110‐2112‐M‐008‐038 – fundername: ; grantid: KMU‐DK(B)111002‐5 |
| GroupedDBID | 0R~ 1OC 24P 53G 5VS 8FE 8FG AAHHS AAYXX AAZKR ABDBF ABJCF ACCFJ ACCMX ACGFS ACUHS ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AEQDE AFKRA AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BCNDV BENPR BGLVJ CCPQU CITATION DIK EBS EJD ESX GROUPED_DOAJ HCIFZ HYE IAO IHR INH ITC KQ8 L6V M7S M~E OK1 PHGZM PHGZT PIMPY PROAC PTHSS RPM TUS AAMMB AEFGJ AGXDD AIDQK AIDYY NPM PQGLB ABUWG AZQEC DWQXO PKEHL PQEST PQQKQ PQUKI WIN 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c539t-3221fb611e1800c129ca473204825b50562cff1e19c60e94fc996876b9438b4a3 |
| IEDL.DBID | BENPR |
| ISSN | 2380-6761 |
| IngestDate | Wed Aug 27 01:07:16 EDT 2025 Thu Aug 21 18:39:38 EDT 2025 Fri Jul 11 04:09:20 EDT 2025 Wed Aug 13 06:28:26 EDT 2025 Thu Jul 24 03:25:23 EDT 2025 Tue Jul 01 04:00:24 EDT 2025 Thu Apr 24 23:07:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | target‐captured ELISA PS‐SPR monoclonal antibody SARS‐CoV‐2 spike rapid antigen test spike |
| Language | English |
| License | 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-3221fb611e1800c129ca473204825b50562cff1e19c60e94fc996876b9438b4a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding information Kaohsiung Medical University, Grant/Award Number: KMU‐DK(B)111002‐5; Ministry of Science and Technology, Taiwan, Grant/Award Numbers: MOST 107‐2923‐B‐005‐005‐MY3, MOST 108‐2112‐M‐131‐002‐MY3, MOST 108‐2320‐B‐037‐035‐MY3, MOST 108‐2918‐I‐037‐001, MOST 110‐2112‐M‐008‐038; Kaohsiung Medical University Research Center Grant, Grant/Award Number: KMU‐TC111B01 Chih‐Yen Lin, Wen‐Hung Wang, and Meng‐Chi Li equally contributed to this study. |
| ORCID | 0000-0003-0731-3758 |
| OpenAccessLink | https://www.proquest.com/docview/2862154864?pq-origsite=%requestingapplication% |
| PMID | 36248235 |
| PQID | 2862154864 |
| PQPubID | 4368370 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_34985401d26d4936ba57c67d315953c5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9538096 proquest_miscellaneous_2725441269 proquest_journals_2862154864 pubmed_primary_36248235 crossref_citationtrail_10_1002_btm2_10410 crossref_primary_10_1002_btm2_10410 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-01 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken – name: Hoboken, USA |
| PublicationTitle | Bioengineering & translational medicine |
| PublicationTitleAlternate | Bioeng Transl Med |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley |
| References | e_1_2_9_75_1 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_73_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_56_1 e_1_2_9_77_1 e_1_2_9_12_1 Kakodkar P (e_1_2_9_21_1) 2020; 12 e_1_2_9_33_1 e_1_2_9_54_1 e_1_2_9_71_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_58_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_68_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_74_1 e_1_2_9_51_1 e_1_2_9_72_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_78_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_76_1 Al‐Tawfiq JA (e_1_2_9_9_1) 2020; 28 e_1_2_9_70_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_61_1 e_1_2_9_46_1 e_1_2_9_67_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_65_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_69_1 e_1_2_9_29_1 |
| References_xml | – ident: e_1_2_9_29_1 doi: 10.1080/14737159.2020.1757437 – ident: e_1_2_9_2_1 doi: 10.1016/j.cell.2021.08.017 – ident: e_1_2_9_38_1 doi: 10.1021/acssensors.1c02215 – ident: e_1_2_9_60_1 doi: 10.3389/fmolb.2021.607886 – ident: e_1_2_9_67_1 doi: 10.1016/S0966-842X(96)10076-7 – ident: e_1_2_9_63_1 doi: 10.1007/s42485-021-00060-3 – ident: e_1_2_9_16_1 doi: 10.1038/s41467-021-26401-w – ident: e_1_2_9_66_1 doi: 10.1128/JVI.00635-20 – ident: e_1_2_9_28_1 doi: 10.1016/j.cca.2020.03.009 – ident: e_1_2_9_30_1 doi: 10.1016/j.bios.2021.113649 – ident: e_1_2_9_19_1 doi: 10.3390/genes12010016 – ident: e_1_2_9_68_1 doi: 10.1128/jvi.70.6.3852-3862.1996 – ident: e_1_2_9_24_1 doi: 10.3389/fimmu.2021.732756 – ident: e_1_2_9_42_1 doi: 10.1016/j.bios.2016.01.040 – ident: e_1_2_9_7_1 doi: 10.1001/jama.2020.0757 – ident: e_1_2_9_46_1 doi: 10.1016/j.optcom.2015.06.011 – ident: e_1_2_9_65_1 doi: 10.1016/j.bsheal.2020.08.004 – ident: e_1_2_9_12_1 doi: 10.1038/s41467-021-22785-x – ident: e_1_2_9_13_1 doi: 10.1186/s13578-021-00643-z – ident: e_1_2_9_36_1 doi: 10.1016/j.bios.2016.06.064 – ident: e_1_2_9_41_1 doi: 10.1021/acs.analchem.6b03511 – ident: e_1_2_9_74_1 doi: 10.7717/peerj.10234 – ident: e_1_2_9_39_1 doi: 10.3390/chemosensors9120330 – ident: e_1_2_9_70_1 doi: 10.3390/v13010046 – ident: e_1_2_9_62_1 doi: 10.2217/fvl-2020-0204 – ident: e_1_2_9_40_1 doi: 10.1007/s00604-021-04974-z – ident: e_1_2_9_44_1 doi: 10.1021/acs.analchem.1c01093 – ident: e_1_2_9_20_1 doi: 10.1016/j.diagmicrobio.2020.115094 – ident: e_1_2_9_61_1 doi: 10.1007/s40588-021-00157-9 – ident: e_1_2_9_71_1 doi: 10.1016/j.bios.2021.113595 – ident: e_1_2_9_11_1 – ident: e_1_2_9_64_1 doi: 10.7150/ijbs.59184 – ident: e_1_2_9_78_1 doi: 10.3390/diagnostics11071190 – ident: e_1_2_9_57_1 doi: 10.1038/s41467-020-18319-6 – volume: 28 start-page: 64 issue: 1 year: 2020 ident: e_1_2_9_9_1 article-title: Preparing for emerging respiratory pathogens such as SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 publication-title: Infez Med – ident: e_1_2_9_43_1 doi: 10.1016/j.bios.2017.01.043 – ident: e_1_2_9_31_1 doi: 10.1021/acs.analchem.0c05438 – ident: e_1_2_9_22_1 doi: 10.1016/j.jiph.2020.03.019 – ident: e_1_2_9_3_1 doi: 10.1038/s41586-020-2012-7 – volume: 12 issue: 4 year: 2020 ident: e_1_2_9_21_1 article-title: A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID‐19) publication-title: Cureus – ident: e_1_2_9_52_1 doi: 10.1016/j.gendis.2020.07.006 – ident: e_1_2_9_56_1 doi: 10.1128/JCM.43.4.1851-1857.2005 – ident: e_1_2_9_23_1 doi: 10.1038/s41563-020-00906-z – ident: e_1_2_9_76_1 doi: 10.1016/j.lanwpc.2021.100276 – ident: e_1_2_9_8_1 doi: 10.1002/jmv.1890060309 – ident: e_1_2_9_27_1 doi: 10.1128/jvi.01837-21 – ident: e_1_2_9_10_1 doi: 10.14202/vetworld.2021.190-199 – ident: e_1_2_9_5_1 doi: 10.1038/s41579-020-00459-7 – ident: e_1_2_9_18_1 doi: 10.3390/ijms22063060 – ident: e_1_2_9_53_1 doi: 10.1016/j.bbrc.2009.03.119 – ident: e_1_2_9_75_1 doi: 10.1038/s41579-021-00573-0 – ident: e_1_2_9_59_1 doi: 10.1038/s41586-020-2180-5 – ident: e_1_2_9_45_1 doi: 10.1016/j.bios.2018.03.051 – ident: e_1_2_9_14_1 doi: 10.1038/s41580-021-00418-x – ident: e_1_2_9_47_1 doi: 10.3390/bios11030075 – ident: e_1_2_9_72_1 doi: 10.1016/j.bios.2020.112715 – ident: e_1_2_9_4_1 doi: 10.1056/NEJMoa2001017 – ident: e_1_2_9_17_1 doi: 10.3390/biology10090880 – ident: e_1_2_9_58_1 doi: 10.1016/j.cell.2022.01.001 – ident: e_1_2_9_32_1 doi: 10.1016/j.bios.2021.113497 – ident: e_1_2_9_77_1 doi: 10.7554/eLife.70658 – ident: e_1_2_9_51_1 doi: 10.1038/s41587-020-0631-z – ident: e_1_2_9_48_1 doi: 10.3390/s21227615 – ident: e_1_2_9_69_1 doi: 10.1016/j.molmed.2004.03.003 – ident: e_1_2_9_55_1 doi: 10.1016/j.jviromet.2014.10.019 – ident: e_1_2_9_15_1 doi: 10.1073/pnas.2003138117 – ident: e_1_2_9_34_1 doi: 10.3389/fmed.2021.797109 – ident: e_1_2_9_54_1 doi: 10.1016/j.dci.2016.10.010 – ident: e_1_2_9_73_1 doi: 10.1038/s41467-021-27369-3 – ident: e_1_2_9_6_1 doi: 10.1002/rmv.2282 – ident: e_1_2_9_26_1 – ident: e_1_2_9_37_1 doi: 10.1021/acs.analchem.7b03934 – ident: e_1_2_9_50_1 doi: 10.1038/nmeth.2570 – ident: e_1_2_9_49_1 doi: 10.1073/pnas.1815329116 – ident: e_1_2_9_33_1 doi: 10.1021/acsnano.0c10035 – ident: e_1_2_9_25_1 doi: 10.1016/j.pathol.2020.09.006 – ident: e_1_2_9_35_1 doi: 10.1021/acssynbio.1c00499 |
| SSID | ssj0001613384 |
| Score | 2.2715387 |
| Snippet | The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered... The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in late 2019 leading to the COVID-19 disease pandemic that triggered... Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus emerged in late 2019 leading to the COVID‐19 disease pandemic that triggered... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e10410 |
| SubjectTerms | Antibodies Antigens Assaying Biosensors COVID-19 Disease Laboratories Monoclonal antibodies monoclonal antibody Polymerase chain reaction Proteins PS‐SPR Respiratory diseases SARS‐CoV‐2 Sensitivity analysis Severe acute respiratory syndrome coronavirus 2 spike spike rapid antigen test Surface plasmon resonance target‐captured ELISA Viral diseases Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT3BAlGdoQYPgwiHqxq_ER4qoKiQ4Uam3yK-IRRCv8kDit_BnGTvZNIsqceFqO5Hjmcl8Y4-_IeRNpIjxqEm5117kXHieK2tYrg0tPK_MRpq43_Hps7y84h-vxfWq1FfMCZvogaeFO2NcVYgqCkel44pJo0VpZekY-mHBbGIvRZ-3Cqa-TTgGYy--8JHSMzP8oPFAM16VXXmgRNR_G7r8O0ly5XUuHpD7M1yEd9M0j8kd3z4k91Ykgo_I7_MQ-pi8DIjlwPkhJVe1sLu5EgChAfSAvvOg7Th46G4O2GHPWQA2khnon9tu7IECQtAB5io-oPHxtk9pRhB2afsbzDbExtBB3MsFhOfQj5E3GVtQXFsT3K_H5Oriw5f3l_lcciG3gqkhR_MuGiOLwheIJC2CAat5ySK7LxUmoSXbNNirrNx4xRuL8RL-UI3irDJcsyfkqA2tf0ZgUzpjK-GoQ1RYeKeY3jCMVk0jrBZWZOTtXgy1nfnIY1mM7_XEpEzrKLI6iSwjr5exu4mF49ZR51Gay4jInJ0aUJ_qWZ_qf-lTRk73ulDP5tzXFOO-GNtJnpFXSzcaYjxd0a0PI44pI9tbQaXKyNNJdZaZIErABWT48vJAqQ6metjTbr8msm-cVIVh5vP_8W0n5C5FjDalyJ2So6Eb_QvEVIN5mcznD4_rIfk priority: 102 providerName: Directory of Open Access Journals |
| Title | Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36248235 https://www.proquest.com/docview/2862154864 https://www.proquest.com/docview/2725441269 https://pubmed.ncbi.nlm.nih.gov/PMC9538096 https://doaj.org/article/34985401d26d4936ba57c67d315953c5 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZo9wKHijcLZWUEFw5RN34lOaEGulRIVAhRqbfIdpyyEsTbJIvEb-HPMuNks7uo4mo70SgzY38znnxDyBukiHFgSZHTTkZCOhFl1vBIGxY7kZq5Mpjv-Hyhzi_Fpyt5NSTc2qGscrMnho269BZz5CcMoDfCayXerW4i7BqFt6tDC40DMoEtOIXga5KfXXz5us2yKIzBxMhLyk5M95PhxSb-MrtzEgXC_ttQ5r_Fkjunz-I-ORpgIz3t9fyA3HH1Q3Jvh0zwEfmTe99iETMFTEdL14Uiq5qutr8GUF9ROAld46i2687RZnvRTjfcBdQiqYH-tWzWLWUUoGhHh24-VMPjdRvKjahfhTQ4NUuPg76hmNOlANNpu0b-ZBgBtS2NL38_JpeLs2_vz6Oh9UJkJc-6CNw8royKYxcDorQACqwWCUeWXyZNQE22qmA2s2ruMlFZiJtgYzWZ4KkRmj8hh7Wv3TNC50lpbCpLVgI6jF2ZcT3nELWaSlotrZyStxs1FHbgJcf2GD-KnlGZFaiyIqhsSl6Pa1c9G8etq3LU5rgCGbTDgG-ui8EhCy6yFNBqXDJViowro2ViVVJywHeSo1jHG1soBrdui60RTsmrcRocEm9ZdO38GtYkyPoWM5VNydPedEZJAC3AB-Tw8mTPqPZE3Z-pl98D6TcIlUK4-fz_Yr0gdxmgsL4I7pgcds3avQTU1JkZOUgXH2dkcpp_yBezwVFmIQfxF7tVH-U |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOQAHxLMsFBgEHDhE3fiRxwEhCpQtfZxaqbdgOw6sBPGSZEH9LfwHfiMzeewDVdx6tb3RaGfG_mY8_oaxF0QR49CSAqedCqRyMkitEYE2PHQyMePIUL7j6DianMpPZ-psg_0Z3sJQWeWwJ7Ybde4t5ch3OEJvgteRfDP7EVDXKLpdHVpodGZx4M5_YchWv95_j_p9yfneh5N3k6DvKhBYJdImQAsOCxOFoQsRLFk876yWsSACW65MCwhsUeBsaqOxS2VhMSTAPcOkUiRGaoHfvcKuSiFS8qhk7-MypxNRxCcXLKh8xzTfOV2j0gPdlXOvbQ9wEab9tzRz5azbu8Vu9iAV3nZWdZttuPIOu7FCXXiX_d71vqaSaUAECblr2pKuEmbLhwjgC8Bz11UOtJ03DqrltT4MTAlgiUJB_5xW8xo4IPBtoO8dBBp_XtZtcRP4WZt0BzP1NOgroAwyYFAA9ZzYmnEEjWRqfH5-j51eikrus83Sl-4Bg3GcG5uonOeIRUOXp0KPBcbIplBWK6tG7NWghsz2LOjUjONb1vE384xUlrUqG7Hni7WzjvvjwlW7pM3FCuLrbgd89SXr3T8TMk0QG4c5j3KZishoFdsozgWiSSVIrO3BFrJ-E6mzpcmP2LPFNLo_3eno0vk5romJYy7kUTpiW53pLCRBbIJ_oMCPx2tGtSbq-kw5_dpSjKNQCQa3D_8v1lN2bXJydJgd7h8fPGLXOeK_rvxum2021dw9RrzWmCetkwD7fNle-RfCF1Wg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKiE4IN4EChgBBw6rZP3YxwEhQhu1FKIKUam3re310khlHXY3oP4W_gm_jpl9JUEVt15tZzXKjMffjMffEPIKKWIsWJJnlZWekFZ4sdHcU5r5VkR6HGjMd3yeBfvH4uOJPNkif7q3MFhW2fnE2lGnzmCOfMQAeiO8DsQoa8sijnan7xY_POwghTetXTuNxkQO7cUvCN_Ktwe7oOvXjE33vn7Y99oOA56RPK48sGY_04HvWx-Ak4GzzygRciSzZVLX4MBkGczGJhjbWGQGwgPwHzoWPNJCcfjuNbIdQlQ0HpDtyd7s6MsqwxNg_Cd6TlQ20tV3hpeq-Fx37RSsmwVchnD_LdRcO_mmt8mtFrLS942N3SFbNr9Lbq4RGd4jvyfOlVhATQFP0tRWdYFXTherZwnUZRROYVtYqsyysrRYXfLTjjeBGiRUUD_nxbKkjAIMrmjbSYgq-Hle1qVO1C3qFDzVc4eDrqCYT6YQItByidzNMAImM9cuvbhPjq9EKQ_IIHe5fUToOEy1iWTKUkCmvk1jrsYcImadSaOkkUPyplNDYlpOdGzNcZ40bM4sQZUltcqG5GW_dtEwgVy6aoLa7Fcge3c94IpvSesMEi7iCJCyn7IgFTEPtJKhCcKUA7aUHMXa6WwhaV1Kmaw2wJC86KfBGeANj8qtW8KaEBnnfBbEQ_KwMZ1eEkAq8Ady-Hi4YVQbom7O5POzmnAchIog1H38f7Gek-uwI5NPB7PDJ-QGAzDY1OLtkEFVLO1TAG-VftbuEkpOr3pj_gUqZ1sy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Boosting+the+detection+performance+of+severe+acute+respiratory+syndrome+coronavirus+2+test+through+a+sensitive+optical+biosensor+with+new+superior+antibody&rft.jtitle=Bioengineering+%26+translational+medicine&rft.au=Lin%2C+Chih%E2%80%90Yen&rft.au=Wang%2C+Wen%E2%80%90Hung&rft.au=Li%2C+Meng%E2%80%90Chi&rft.au=Lin%2C+Yu%E2%80%90Ting&rft.date=2023-09-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=2380-6761&rft_id=info:doi/10.1002%2Fbtm2.10410&rft.externalDocID=PMC9538096 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2380-6761&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2380-6761&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2380-6761&client=summon |